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ZUSAMMENFASSUNG FÜR LAIEN 
Lebererkrankungen betreffen weltweit Millionen von Menschen und die Anzahl der 
Neuerkrankungen steigt stetig. Während sich die Überlebensraten für die meisten Krankheiten in den 
letzten Jahrzehnten verbessert haben, stellen Lebererkrankungen nach wie vor eine erhebliche 
Belastung für das Gesundheitssystem dar. Gegenwärtige Therapien bei Erkrankungen der 
Leberzellen (Hepatozyten) sind unzureichend und behandeln in den meisten Fällen nur die 
Symptome. Daher sind verbesserte Therapiemöglichkeiten dringend erforderlich. Der zielgerichtete 
Einsatz von Nanopartikeln für den Transport von Wirkstoffen oder genetischem Material zu einem 
bestimmten Zelltyp hat das Potenzial, den Mangel an zufriedenstellenden und alternativen 
Behandlungsmöglichkeiten zu überwinden. Diese Doktorarbeit hat sich auf die Entwicklung von 
neuartigen, nanomedizinischen Ansätzen für den gezielten Arzneimitteltransport zu Hepatozyten 
spezialisiert (Schlüssel-Schloss-Prinzip). Diese Technologien bieten die Möglichkeit, Medikamente 
spezifisch zu Leberzellen zu transportieren und damit einen bestimmten Zelltyp in der Leber 
anzusteuern. Das Projekt bestand aus zwei Hauptzielen, die wie folgt zusammengefasst werden 
können: 
 
Erstens wurden Strategien für eine spezifische und hochselektive Arzneimittelabgabe an 
Hepatozyten über den Asialoglycoproteinrezeptor (Schloss) untersucht. Dieser Rezeptor wird in 
großem Ausmaß und fast ausschließlich auf Hepatozyten gebildet. Nach der spezifischen Bindung 
von Nanopartikeln (Arzneimittel-Transportsystem) an den Ziel-Rezeptor (Schlüssel-Schloss-Prinzip) 
werden die Nanopartikel in die Leberzellen aufgenommen. Um herauszufinden ob diese gezielte 
Therapie prinzipiell möglich ist, wurde die Häufigkeit des Zielrezeptors auf Hepatozyten untersucht. 
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Dazu wurden mehrere menschliche Leberzelllinien und Gewebeproben von Patienten, welche an 
verschiedenen Lebererkrankungen leiden, untersucht. Um die Durchführbarkeit einer zielgerichteten 
nanomedizinischen Therapie aufzuzeigen, wurden Nanopartikel auf der Oberfläche mit 
Glycoproteinen (Schlüssel) modifiziert und dann in menschlichen Zellen (in vitro) und in lebenden 
Organismen (in vivo) getestet. Um die Arzneimittel-Transport-Systeme weiter zu verbessern, wurden 
zusätzliche von Glycoproteinen abgeleitete Liganden (Schlüssel), wie z.B. komplexe Kohlenhydrate 
oder einfache Zucker, untersucht. Um zu untersuchen wie Nanopartikel in Zellen aufgenommen und 
dann weiter transportiert werden, wurden darüber hinaus neue Technologien entwickelt.  
 
Zweitens wurden neuartige Nanopartikel für eine verbesserte Beladung mit genetischem 
Material (Erbgut) entwickelt um dieses gezielt zu bestimmten Zellen zu transportieren. Der Fokus 
dabei waren Nanomaterialien, die sich für eine intravenöse Verabreichung in Patienten eignen. Dazu 
wurden die physikalisch-chemischen Eigenschaften der mit Erbgut-beladenen-Nanopartikel 
charakterisiert und die effektive und sichere Einbringung von genetischem Material in menschlichen 
Zellen getestet. 
 
Zusammengefasst war diese Doktorarbeit der erste Schritt zur Entwicklung neuartiger 
Hepatozyten-spezifischer Nanopartikel, welche die eingeschlossenen Wirkstoffe schützen und den 
zellspezifischen Transport effizient und ohne Nebenwirkungen ermöglichen. Diese Strategie ist von 
großem Interesse für diagnostische und therapeutische Anwendungen bei der Behandlung einer 
Vielzahl von Lebererkrankungen. 
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SUMMARY 
Hepatic disorders affect millions of people around the globe and incidence rates are further 
increasing. While survival rates have improved for most diseases during recent decades, liver diseases 
still represent a considerable public health burden. Current therapies for diseases of hepatocytes are 
limited and in most cases only treat symptoms. Therefore, improved therapeutic technologies are 
urgently needed. Targeted nanomedicines for the delivery of small molecules or nucleic acids have 
the potential to overcome the lack of satisfactory and alternative treatment options. This PhD 
project focused on the development of novel nanomedicines for targeted drug delivery to liver 
parenchymal cells. These technologies offer the possibility to specifically target drugs to hepatocytes, 
thus giving access to a defined cell type within the liver. The project consisted of two major 
objectives, which can be summarized as follows: 
  
First, targeting approaches for specific and highly selective drug delivery to hepatocytes via 
the asialoglycoprotein receptor (ASGPR) were evaluated. This receptor is abundantly and almost 
exclusively expressed on hepatocytes. After binding to its target, the drug delivery system is 
internalized by receptor-mediated endocytosis. The applicability of this targeting approach was 
evaluated by analysis of ASGPR expression. Human tissue samples from patients suffering from 
various liver diseases and several liver-derived cell lines were analyzed. As a proof-of-concept study, 
asialofetuin-conjugated liposomal drug carriers were designed and tested in vitro and in vivo. To 
further improve ASGPR-specific nanocarriers, glycoprotein derived targeting ligands including 
multiantennary glycans and monovalent sugars were evaluated. Furthermore, novel technologies 
were developed to investigate the uptake mechanisms and the intracellular fate of nanocarriers. 
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Second, in order to develop nucleic acid delivery systems, new nanomaterials for an 
optimized loading and retention of DNA expression plasmids were evaluated. The focus were 
nanomaterials applicable for a systemic administration in vivo. The physico-chemical properties were 
characterized and the plasmid DNA nanoparticles were screened for efficient and safe transfection 
activity in vitro.  
 
In summary, this PhD project was the first step towards the development of novel 
hepatocyte-targeted nanocarriers, which protect encapsulated drugs and facilitate the cell-specific 
delivery efficiently and with low cytotoxicity. This strategy is of great interest for diagnostic and 
therapeutic medical applications in the treatment of liver disorders. 
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INTRODUCTION 
I. LIVER  
1. Liver Structure and Different Cell Types 
 
 
 
Figure 1: Structure of liver lobules. The hepatic lobule is the functional unit of the liver. Each lobule 
receives blood from the portal vein and the hepatic artery, which terminate in the hepatic sinusoids. 
The bile canaculi transport bile from the liver to the gut. Sinusoidal endothelial cells (SEC) line the 
blood vessels. Tissue-resident macrophages, i.e., Kupffer cells (KC), are interspersed in the lumen of 
hepatic sinusoids. Stellate cells (SC) are located in the perisinusoidal space of Disse. Hepatocytes (HC) 
form the liver parenchyma. Figures are adapted from Mosby and Lau et al. 1,2 
 
ϭ.ϭ.  Liǀeƌ  
Due to its wide range of functions, the liver is one of the most interesting organs in the 
human body (estimated total number of 500 functions). 3–5 It is the key organ for metabolism and 
clearance of endo- and exogenous substances. In addition, the liver is responsible for storage 
(e.g., proteins, fats, vitamins, iron), protein production (e.g., clotting factors), cholesterol homeostasis 
Introduction 
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or immune responses. The hexagonal formed liver lobules are the functional units responsible for 
the different functions. 6 Liver lobules are supplied with oxygen and nutrients by peripheral blood 
from the hepatic artery and the portal vein, which is transported through liver capillaries 
(i.e., sinusoids) to the central vein (Figure 1). 7,8 Each liver lobule consists of parenchymal 
(i.e., hepatocytes, HC) and non-parenchymal liver cells including sinusoidal endothelial cells (SEC), 
hepatic macrophages (Kupffer cells, KC), and stellate cells (ito cells, SC). All cell types will be 
discussed in detail in the next sections.  
 
ϭ.Ϯ. HepatoĐǇtes 
Hepatocytes, also called liver parenchymal cells, are located behind the space of Disse 
separated from the blood by the sinusoids (Figure 1). They represent approximately 70–80% of all 
cells in the liver and have many essential functions including protein synthesis, transformation of 
carbohydrates or metabolism of xenobiotics. 9 The average lifespan of hepatocytes is around 150 
days. Hepatocytes are highly differentiated and exhibit a polarized structure. They have a basolateral 
(sinusoidal) membrane facing the sinusoidal space, an apical side towards the bile canaliculi and a 
lateral surface connecting adjacent parenchymal cells. The basolateral membrane of hepatocytes has a 
large amount of microvilli, therefore increasing the perisinusoidal surface for absorptive processes 
(Figure 2). Besides the functional importance for the human body, the liver parenchymal cells are 
considered as key pro-pathogenic cell type for many disorders. A summary of different hepatic 
diseases, their frequencies, and the therapeutic strategies are discussed in “Section 2”. 
 
ϭ.ϯ. SiŶusoidal EŶdothelial Cells 
The endothelial wall of hepatic blood vessels consists of sinusoidal endothelial cells (SEC) 
(Figure 1). These cells have important morphological and physiological characteristics, which are 
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essential for hepatic metabolism as well as nanoparticulate drug delivery to hepatocytes. During the 
last three decades, Wisse and colleagues have revealed many of these structural and functional 
aspects. 10–14 Importantly, SEC form open pores in the sinusoidal wall, so-called liver fenestrae, which 
allow the exchange of various substances between the blood and parenchymal liver cells via the space 
of Disse. 12 These pores have a size of approximately 100–200 nm in diameter and they are arranged 
as groups of fenestrae, i.e., liver sieve plates (Figure 2). The precise diameter and number of hepatic 
fenestrae in different species are represented in Table 1 and compared to fenestrations in other 
organs/tissues. However, these fenestrae parameters might show inter- and intraindividual variations 
due to drug induced effects or pathological conditions. 15,16  
 
Table 1: Fenestrations of the vasculature. Fenestrations in hepatic blood vessels are given for different 
species. In addition, the fenestrations of vasculature in other organs or pathological tissues are given 
for comparison. The table is adapted from Braet et al. and Gaumet et al. 10,17 
 
Species / Organ 
 
Diameter [nm] Ref. 
 
Hepatocytes   
 Human 50 – 300 
18 
 Rat 98.0 ± 13.0 
19 
 Mouse 99.0 ± 18.0 
20 
 Rabbit 59.4 ± 4.8 
21 
 
Other Organs/Tissues   
 Kidney (rat, rabbit, guinea pig) 20 – 30 
22,23 
 Spleen (mice) 150 
24,25 
 Bone marrow (rat, rabbit, guinea-pig) 85 – 150 
26 
 Skeletal, cardiac and smooth muscle (mice) < 6 
27 
 Tumor (mice) 200 – 780 
28,29 
 Inflamed organs (hamster) 80 – 1400 
30 
 
 
In general, around 6–8% of the sinusoidal surface is fenestrated, therefore giving blood 
components, which are smaller than these pores, direct access to hepatocytes. Recently, among many 
other proposed mechanisms, elevated serum cholesterol levels leading to the development of 
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atherosclerosis have been related to decreased fenestrae size. 19,21,31 In general, chylomicron remnants 
can pass liver fenestrae, whereas large triglyceride-rich chylomicrons are held back in circulation. 
However, if the sieving capacity is impaired, the blood clearance of chylomicron remnants by 
hepatocytes is limited. Therefore, several compounds have been investigated to increase the pore size 
of fenestrae and thus influence the physiological access of lipoproteins to hepatocytes. 10 In case of 
hepatic drug targeting, these pore-opening substances offer interesting therapeutic possibilities to 
modulate the liver fenestration and thus enhance the delivery of nanoparticles to parenchymal liver 
cells. 
 
ϭ.ϰ. Kupffeƌ Cells 
Resident liver macrophages were first described by Carl von Kupffer. 32 Circulating 
monocytes derived from bone marrow differentiate into liver resident macrophages, so-called 
Kupffer cells. These cells are members of the mononuclear phagocyte system (MPS) (or 
reticuloendothelial system, RES) and comprise more than 80% of the total population of tissue 
macrophages in the body. 7,33 They are located in the lumen of hepatic sinusoids in close proximity to 
sinusoidal endothelial cells (Figure 1/2). Due to their prominent location in the body, they are 
involved in various immunological and inflammatory processes. 34 Their endocytic activity is 
important for host defense and elimination of particulate and foreign materials including 
nanoparticles. Periportal-located Kupffer cells are more abundant, possess a greater phagocytic 
potential and have a higher lysosomal enzyme activity as compared to perivenous/midzonal-located 
Kupffer cells. 35 Kupffer cell uptake is mainly mediated by three mechanisms. 36 First, scavenger 
receptors are activated by several factors including highly charged nanoparticles, thus triggering 
endocytosis. Second, carbohydrate receptors including the mannose receptor initiate phagocytosis 
after ligand recognition. Third, nanoparticles, which have been coated in circulation by complement 
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factors (e.g., C3b or C1q) or serum opsonins such as fibronectin, will be cleared by Kupffer cells. In 
order to eliminate unwanted nanoparticle clearance, clodronate loaded liposomes can be injected 
in vivo for the eradication of Kupffer cells. 37,38 
 
      
Figure 2: Liver Sinusoids. (A) Cross section of liver sinusoid, which is lined by sinusoidal endothelial cells 
(SEC). Microvilli on hepatocytes are exposed towards the space of Disse. (B) Lumen of hepatic sinusoid 
with fenestrated endothelium forming sieve plates. (C) Kupffer cell (KC) located in the lumen of 
hepatic sinusoids in close proximity to SEC. Figures are adapted from Cormack et al., Vollmar et al. and 
missinglink.ucsf.edu. 
39–41
 
 
ϭ.ϱ. Stellate Cells 
Hepatic stellate cells (SC) are star-shaped cells located in the perisinusoidal space of Disse 
between the sinusoidal endothelial cell wall and parenchymal liver cells (Figure 1). 8 In literature, 
there are several different names for this cell type including parasinusoidal cells, Ito cells, vitamin A 
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storing cells, or lipid-storing cells. 42 Two different types of stellate cells can be distinguished, a 
quiescent and an activated/transdifferentiated form. 43 In a normal and healthy liver the main 
function of stellate cells is the storage of vitamin A (retinol), which is essential for several growth and 
differentiation processes in the body. Upon liver damage, several mediators induce the differentiation 
of stellate cells into a myofibroblast-like cell type with diverse phenotypic changes. 44  
Platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF-Ƣ) are the 
most important activators stimulating proliferation and fibrogenesis, respectively. The normal 
extracellular matrix remodeling changes qualitatively as well as quantitatively. Activated stellate cells 
produce excessive amounts of connective scar tissue (especially collagen type 1) and in addition 
secrete tissue inhibitors of matrix metalloproteinases (i.e., TIMP-1 and TIMP-2). The replacement of 
normal hepatic tissue with a scar-like matrix finally leads to fibrosis and therefore impairment of the 
physiological transendothelial transport in the liver (Figure 3). 
 
2. Hepatocyte-related Diseases and Their Therapy 
Hepatocytes are the key pro-pathogenic cell type within the liver implicated in various 
diseases. Hepatocellular carcinoma, viral and parasitic infections, or genetic disorders affect millions 
of people worldwide and incidence rates are further increasing (Figure 3). A list of hepatocyte-related 
liver diseases is shown in Table 2. 
 One example from each group is described in more detail in the following sections. These 
summaries also highlight the increasing need for alternative and improved treatment options. The 
targeted delivery of small molecules (e.g., with poor pharmacokinetic properties) or nucleic acids 
(where the pharmacological effect is dependent on cellular uptake) offers a promising strategy for 
therapeutic interventions of these diseases. 
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Figure 3: Liver diseases. (A) During the last decades, the lack of efficient therapeutic options has 
resulted in a strong increase in liver disease rates and mortality (exemplified for the UK). Cirrhosis, liver 
cancer and acute hepatitis caused more than 2 million deaths worldwide in 2010. (B) While survival 
rates have improved for most diseases during the last decades, liver diseases are on the rise and still 
represent a considerable public health burden. (C) The initiation and development of hepatocellular 
carcinoma is a multistep process occurring over years. Liver transplantation is still the only available 
option for many incurable or late-stage liver diseases. Figures are adapted from Williams et al. and 
Pellicoro et al. 45,46 
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Table 2: Summary of hepatocyte-related diseases. Hepatocytes are the key pathogenic cell type for 
many liver disorders including liver cancer, viral or parasitic infections, and genetic diseases. Different 
diseases are summarized and current treatment options are indicated. 
Disease 
Pathophysiology / 
Mechanism 
Symptoms Treatment Prevalence 47 Ref.
Cancer    
Hepatocellular 
Carcinoma (HCC) 
Chronic liver inflammation 
- cirrhosis - HCC 
Liver damage, 
liver cancer 
Curative or 
palliative 
treatment  
16:100,000 and
> 700,000 new 
cases per year 
48–50
Viral Infections    
Hepatitis B Hepatitis B Virus (HBV) 
infection 
Liver damage, 
cirrhosis, HCC 
Interferon ơ, 
nucleos(t)ide 
350 million 
chronic carriers
51–54
Hepatitis C Hepatitis C Virus (HCV) 
infection 
Liver damage, 
cirrhosis, HCC 
Interferon ơ, 
protease 
inhibitors 
180 million 
chronic carriers
51,55
Parasitic Infections   
Malaria Plasmodium vivax / 
Plasmodium ovale  
Fever, severe 
anemia, renal 
failure  
Primaquine, 
chloroquine 
70–390 million 
cases per year 
56–59
Genetic Disease (without 
parenchymal damage) 
 
   
Bilirubin metabolism 
disorders (e.g., Crigler-
Najjar syndrome 1) 
 
Uridine diphosphate 
glucuronosyltransferase 
(UGT1A1) deficiency - 
impairment of bilirubin 
conjugation 
 
Neurological 
damage; kern-
icterus (bilirubin 
encephalopathy) 
Phototherapy 
(10–12h per 
day); Plasma 
exchange 
< 1:1,000,000 60,61
Urea cycle disorders 
(e.g., OTC deficiency) 
 
 
 
Ornithine transcarbamylase 
(OTC) deficiency  
[many other deficiencies 
such as Argininosuccinate 
synthetase (ASS; Citrullin-
aemia), N-acetyl glutamate 
synthetase (NAGS), Carba-
moylphosphate synthetase 
(CPS), Arginase (ARG)] 
 
Hyperammo-
nemia; neuro-
logical damage 
Nitrogen 
scavenger 
therapy, 
hemodialysis 
OTC: 1:80,000 62,63
TTR Familial amyloid 
polyneuropathy (FAP) 
Transthyretin mutation -
deposition of insoluble 
protein 
Neurodegene-
ration, poly-
neuropathy 
Small mole-
cule drugs 
(tafamidis) 
< 1:100,000, 
>in some 
countries 
64,65
Primary hyperoxaluria 
type 1 
Alanine glyoxylate 
aminotransferase mutation 
Calcium oxalate 
accumulation, 
kidney damage 
High fluid 
intake, kid-
ney trans-
plantation 
 
1:333,000–
1,000,000 
62,66
Familial Hyperchol-
esterolemia (e.g., LDL 
receptor related) 
LDL receptor protein 
mutation [also ApoB or 
PCSK9 mutations] 
Coronary artery 
disease 
Statins, LDL 
apheresis 
Homozygous 
<10:1,000,000
Hetero: 1:500  
 
67,68
Hemophilia disorders 
(e.g., Hemophilia B) 
Factor IX deficiency 
[other coagulation factor 
mutations A and C] 
Blood clotting 
disorder, 
hemorrhage 
i.v. infusion 
of coagu-
lation factor 
 
1:20,000 69,70
Thrombotic disorders 
(e.g., Protein C deficiency 
type 1) 
Thrombotic disease caused 
by PROC gene mutation 
[also other inherited 
thrombophilias] 
Risk of 
thrombosis 
Thrombo-
embolism, 
protein C 
substitution 
1:500,000–
750,000 
71,72
(continued on next page)
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Table 2 (continued)  
Disease 
Pathophysiology / 
Mechanism 
Symptoms Treatment Prevalence 47 Ref.
Genetic Disease (with 
parenchymal damage) 
 
   
ơ1-antitrypsin deficiency Mutations in the 
SERPINA1 gene; 
deficiency in protease 
inhibitor for neutrophil 
elastase 
 
Lung and liver 
damage 
Augmen-
tation; 
replacement 
therapy 
1–5:10,000 73,74
Wilson´s disease Copper-transport P-type 
ATPase deficiency, Copper 
accumulation 
 
Liver and neuro-
logical damage 
Copper 
complexation 
1:30,000– 
100,000 
individuals 
75,76
Iron overload disorder 
(e.g., Hereditary hemo-
chromatosis type 1) 
HFE enzyme deficiency 
[other iron dysregulation; 
Type 2: HFE2 or HAMP 
(hepcidin); Type 3: TFR2 
(transferrin receptor 2); 
Type 4: SLC40A1 
(ferroportin)] 
 
Liver cirrhosis, 
insulin resistance 
Phlebotomy, 
iron-
chelating 
Type 1: 
>1:1,000 
Type 2/3/4:  
< 1 : 1,000,000 
 
77,78
Tyrosinemia disorders 
(e.g.,  Tyrosinemia 
type 1) 
Fumarylacetoacetate 
hydrolase (FAH) deficiency 
- lack of tyrosine degra-
dation [other types with 
enzyme deficiency in 
tyrosine metabolism] 
 
Hepatomegaly, 
liver and kidney 
dysfunction 
Nitisinone 
(inhibition of 
tyrosine 
degradation) 
1:100,000 79,80
Glycogen storage 
diseases (GSD) 
(e.g., Pompe´s disease) 
Various types of enzyme 
deficiencies in glycogen 
synthesis 
Hepatomegaly, 
hypoglycemia 
Treatments 
depending 
on type 
1:50,000–
1,000,000 
81,82
 
Ϯ.ϭ. HepatoĐellulaƌ CaƌĐiŶoŵa 
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. 7 More 
than 700´000 new cases are reported each year, with increasing incidence during the last two 
decades. 49,50 Due to its poor prognosis, HCC is the third most common cause of cancer-related 
deaths. The most frequent risk factors for HCC are chronic viral infections, i.e., HBV and HCV, 
which account for approximately 80% of all cases. 51 Patients with cirrhosis are at the highest risk to 
develop HCC. Other risk factors are alcohol abuse, toxins (e.g., aflatoxin B1), or genetic liver 
disorders including hereditary hemochromatosis, Wilson´s disease, or ơ1-antitrypsin deficiency. 48 
The development of HCC is a complex multistep and multifactorial process (Figure 3C). 50 
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Depending on the stage of HCC different curative or palliative treatment options are available. The 
Barcelona Clinic Liver Cancer (BCLC) strategy establishes treatment recommendations for all five 
stages of HCC. 50 In early stages three treatment options are recommended including surgical 
resection, liver transplantation, or ablation. The most frequently used form of local ablation therapy 
is radiofrequency ablation (RFA). Alternatively, injection of chemicals (e.g., ethanol) or other physical 
methods (e.g., microwave, cryoablation) can be used to induce tumor necrosis. For intermediate 
stages of HCC, only palliative treatment options are available. Transarterial chemoembolization 
(TACE) is the method of choice. Microparticles coated with chemotherapeutic agents are used to 
obstruct the arterial blood supply of the tumor and thus induce ischemic tumor necrosis. The 
multikinase inhibitor sorafenib is the only first-line therapeutic option for advanced stages of HCC. 
Many other antiproliferative and antiangiogenic compounds or biologicals are currently investigated 
in clinical trials. The discovery of biomarkers for early detection of HCC is an increasing field of 
research. Thus, therapeutic regimens could be personalized and clinical outcomes might be 
improved.  
 
Ϯ.Ϯ. IŶfeĐtioŶs 
 Viƌuses ;Hepatitis B ViƌusͿ 
Hepatitis B virus (HBV) infection is one of the major causes for the development of cirrhosis 
and liver cancer. Approximately 50% of all HCC cases are caused by chronic HBV infection. 50 More 
than 350 million people are chronically infected worldwide and around 800´000 people die each year 
due to HBV infection. 54 There are three major modes of transmission: first, transmission from 
HBV-infected mothers to their newborn, second, sexual transmission, and third, transmission via 
blood caused by blood transfusions, dialysis, or contaminated needles (e.g., drug abuse). 53 HBV 
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infection can be prevented efficiently by avoidance of transmission or vaccination. However, the 
global vaccination coverage strongly varies. Thus, a total number of around 2 billion people have 
been infected worldwide (17.5% are still chronically infected) and almost 100´000 new cases are 
reported each year. 54 One of the reasons for these high numbers is the high infectious potential of 
the HBV. It has been reported that 1–10 virus particles are sufficient to infect a chimpanzee with 
hepatitis B. 83 After transmission, the HBV specifically enters hepatocytes via the sodium-
taurocholate cotransporting polypeptide (NTCP/SLC10A1). 84,85  
The replication in parenchymal liver cells finally results in an immune system activation 
(i.e., cytotoxic T-lymphocytes) and induction of necroinflammatory liver disease. 52 This immune-
mediated liver damage will further progress into its final stages of cirrhosis and liver cancer. For the 
treatment of HBV two therapeutic options are available: First, interferon ơ-2a is used owing to its 
antiviral and immunostimulatory activity. 86 Second, nucleoside (i.e., lamivudine, entecavir, 
telbivudine) and nucleotide analoga (i.e., adefovir, tenofovir) are used to inhibit the viral polymerase 
and reverse transcriptase activity. 53 Notably, both therapies are not curative. In addition, both 
therapeutic options suffer from significant drawbacks. Interferon therapy has severe side effects and 
nucleos(t)ide analoga show a high risk of developing resistance. 87 Several other strategies to treat 
HBV-infected patients are in clinical trials including the first HBV entry inhibitor Myrcludex B. 88 
 
 Paƌasites ;Malaƌia ViǀaǆͿ 
Malaria is an infectious disease caused by Plasmodium parasites. After the bite of an infected 
female Anopheles mosquito, the Plasmodium sporozoites quickly enter the human body. 89 They 
migrate to the liver, cross the sinusoids and enter hepatocytes. Inside hepatocytes, sporozoites 
develop into thousands of merozoites, which will finally be released into the blood. After erythrocyte 
invasion, merozoites replicate until the red blood cells are disrupted and the erythrocytic cycle starts 
Introduction 
 
using active targeted nanomedicines”  21 
again. This phenomenon causes the typical malaria symptom of recurrent paroxysmal fever at 
intervals of 48/72 hours. 90 In total, five different Plasmodium species can infect human beings, 
i.e., P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. The most severe infection is 
caused by P. falciparum. All other forms are often assumed as benign, because they have a lower 
mortality and morbidity rate. However, this misleading view has changed in recent years for several 
reasons. 56 First, P. vivax is responsible for up to 40% of all malaria cases and causes up to 390 
million new clinical cases each year, mainly in Southeast Asia and South America. 57,90 Second, 
P. vivax causes serious and life-threatening syndromes similar to P. falciparum including severe 
anemia, renal failure, and hepatic dysfunction. 90 Third, P. vivax (also P. ovale) has a special 
exoerythrocytic lifecycle. Some of the hepatic sporozoites do not develop into merozoites and thus 
result in dormant liver forms so-called hypnozoites. 89  
This reservoir of infectious parasites can cause disease relapses months and even years after 
the first infection. 58,91 The only treatment option against hypnozoites is the 8-aminoquinoline 
derivate primaquine. 59 However, high doses of primaquine (15 mg/day for 2 weeks or 45 mg/week 
for 8 weeks) are needed because of its poor pharmacokinetic properties. 91 In addition, primaquine 
can cause severe cytotoxic effects. The dose limiting hemolytic toxicity is especially pronounced in 
patients having a glucose-6-phosphate dehydrogenase (G6PD)-deficiency. 92 Unfortunately, G6PD-
deficiency is most common in malaria vivax-endemic regions with 5–10% of all people having a 
decreased G6PD activity. 91 Therefore, new treatment options to treat dormant liver stages of 
Plasmodia (i.e., hypnozoites) are urgently needed. 58,59 
 
Ϯ.ϯ. GeŶetiĐ Diseases  
Due to the lack of curative treatments for many inherited liver disorders, gene-replacement 
therapies using hepatocyte-directed nanomedicines offer interesting therapeutic options. 62 In the 
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following sections, two exemplary monogenetic liver diseases are described in detail. These examples 
were chosen because of available animal models which facilitate the development of hepatocyte-
directed gene therapy approaches. 
 
 BiliƌuďiŶ Metaďolisŵ Disoƌdeƌ ;e.g., Cƌigleƌ-Najjaƌ SǇŶdƌoŵeͿ 
Disorders of bilirubin transport and its metabolism result in systemic accumulation of 
bilirubin. In patients with Rotor syndrome or Dubin-Johnson syndrome, the transport of conjugated 
bilirubin is impaired due to reduced hepatic uptake or biliary secretion, respectively. 61 Notably, these 
two bilirubin disorders are asymptomatic. By contrast, the impairment of bilirubin glucuronidation 
due to defects in a gene encoding for UDP-glucuronosyltransferase 1A1 (UGT1A1, a 59 kDa protein 
of 533 AA located in the endoplasmic reticulum) results in hyperbilirubinemia and clinical 
manifestations including jaundice. Gilbert`s syndrome, also called Gilbert-Meulengracht syndrome, is 
a mild form of unconjugated hyperbilirubinemia. Phenobarbital treatment reduces the bilirubin levels 
below neurotoxic levels. 93 The complete loss of UGT1A1 function leads to a severe form of 
jaundice, called hereditary Crigler-Najjar syndrome type 1 (1 case per 1’000’000 births). 62 Without 
treatment, the excessive unconjugated bilirubin levels cause neurological damages with the final stage 
of lethal encephalopathy (kernicterus). The only available symptomatic treatment consists of 
phototherapy for 10 to 12 hours a day to reduce elevated bilirubin levels. At present, liver 
transplantation is the only curative therapeutic option. 94 To study hepatocyte-directed gene therapy 
approaches, the Gunn rat is the animal model of choice for Crigler-Najjar syndrome type 1. 95,96 
 
 Uƌea CǇĐle Disoƌdeƌ ;e.g., OƌŶithiŶe TƌaŶsĐaƌďaŵǇlase DefiĐieŶĐǇͿ  
Urea cycle disorders lead to elevated ammonia levels. Without treatment, the hyperammonia 
results in severe metabolic encephalopathy. 97 The reasons for this metabolic impairment are 
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manifold, since many enzymes in the urea cycle can be mutated. In total, urea cycle disorders have an 
incidence of around 1:20`000. The most common disorder is ornithine transcarbamylase (OTC) 
deficiency (1 case per 80’000 births). 62  
Other urea cycle disorders are N-acetyl glutamate synthetase (NAGS) deficiency, Carbamoyl 
phosphate synthetase (CPS) deficiency, Argininosuccinate lyase (ASL) deficiency (Argininosuccinic 
aciduria), Arginase (ARG) deficiency (Argininemia), or Argininosuccinate synthetase (ASS) deficiency 
(Citrullinaemia). The most important treatment options are dietary to reduce the protein intake and 
removal of excessive ammonia from the blood using nitrogen scavenger therapy or hemodialysis. 63 
Liver transplantation represents the only curative treatment for urea cycle disorders, especially for 
neonatal OTC deficiency. The spf/ash mouse model can be used to study gene therapy approaches 
in vivo. 98,99 
 
II. Nanomedicine – Drug Delivery and Drug Targeting 
1. Drug Delivery Technologies 
Nanoparticulate drug delivery systems offer a huge potential for the therapy of liver 
disorders. 100,101 The general concepts and advantages of nanomedicine-based therapeutics are 
explained in detail in Chapter I of the “Results” section for the treatment of cancer. 102 However, 
these strategies are also applicable for therapeutic interventions of hepatic diseases in order to 
enhance efficacy and reduce toxic side effects of administered drugs. 101 The strategy might change 
depending on the type of disease or drug to be delivered. For example, liver structure, accessibility of 
target cells, or target receptor expression might change during disease progression. Therefore, the 
targeting strategy and type of nanomaterial have to be chosen carefully to design a nanocarrier with 
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an increased therapeutic benefit. Two main groups of nanomaterials were used during this PhD 
project, namely lipid- or polymer-based materials. 103–105 In the following sections, these drug delivery 
systems and targeting strategies are described with a focus on hepatocytes and the barriers, which 
need to be overcome.  
 
 
Figure 4: Lipid and polymer-based nanoparticles. (A) Different nanoparticle structures for lipid and 
polymer-based drug delivery systems are shown. Hydrophilic and/or lipophilic drugs can be 
encapsulated. (B) Conventional nanoparticles can be functionalized to endow stealth, targeted, or 
theranostic drug delivery systems. Figure A is adapted from Wicki & Witzigmann et al. 102 
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ϭ.ϭ. Lipid-ďased NaŶoŵediĐiŶes 
The use of lipid-based vesicles as drug delivery system was first described by Gregory 
Gregoriadis in 1971. 106 He discovered that liposomes, which were initially called “banghasomes” 
(after their discoverer Alec Bangham) 107,108, change the pharmacokinetic behavior of encapsulated 
drugs. Based on their structure, lipid-based nanomedicines can be divided into two groups: 
liposomes and solid lipid nanoparticles (Figure 4). 109 Both lipid systems are multicomponent 
nanomedicines consisting of various lipids, mainly phospholipids, optionally cholesterol as a 
stabilizer (i.e., to decrease leakage) and the drug of interest. 110 Liposomes are vesicles with a 
hydrophilic cavity and a lipophilic membrane, whereas solid lipid nanoparticles are solid spheres, 
which are surrounded by a lipid monolayer. Depending on the encapsulated drug and formulation 
method, either hollow or solid lipid-based nanoparticles will be generated. Hydrophilic drugs can be 
encapsulated inside liposomes, whereas lipophilic drugs can be incorporated in the lipid bilayer. Solid 
lipid nanoparticles can encapsulate drugs such as nucleic acids inside the nanoparticle core.  
Today, lipid-based nanomedicines are the most advanced nanoparticulate drug delivery 
systems with several formulations in clinical use. 109 Chapter I of the “Results” section describes in 
detail some of these advances. Several other excellent reviews discuss the field of lipid-based 
nanomedicines and their advantages for drug delivery in detail. 102,109,111–114 The reader is advised to 
read these publications for further information. 
 
ϭ.Ϯ. PolǇŵeƌ-ďased NaŶoŵediĐiŶes 
Polymer-based nanomedicines are another type of nanoparticulate drug delivery system used 
to modulate the pharmacokinetic and pharmacodynamics profile of drugs. In general, polymer-based 
nanomedicines consist of natural (e.g., proteins or glycans) or synthetic polymers (especially block 
copolymers consisting of a stealth, hydrophilic block and a lipophilic block). 102 The huge advantage 
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of synthetic polymers for therapeutic applications is their great chemical variability. 115 This offers the 
possibility to influence nanoparticle structure, to modify the surface with targeting ligands or to 
implement responsiveness to internal or external stimuli. Based on their structure polymer-based 
nanomedicines can be divided into vesicles (i.e., polymersomes), polymer nanoparticles (i.e., solid 
spheres), micelles or layer-by-layer capsules (Figure 4). The different forms and their advantages are 
described in detail in Chapter II of the “Results” section. 115 In addition, several excellent reviews 
summarize the field of polymer-based nanomedicines. 116–118 
 
 
2. Drug Targeting Strategies 
The general concepts of passive or active targeting and triggered drug release are described in 
Chapter I/II of the “Results” section. 102 This paragraph focuses on the various factors, which have 
to be considered to overcome the different hurdles for successful hepatocyte-specific drug delivery 
(Figure 5A). In addition, the targeting of the hepatic ASGPR is described in detail. Different 
targeting ligands are evaluated and recent drug targeting systems from research projects and clinical 
trials are emphasized. 
 
Ϯ.ϭ.  AĐtiǀe TaƌgetiŶg of HepatoĐǇtes 
The implementation of active drug targeting strategies to parenchymal liver cells offers a 
huge potential for therapeutic interventions of liver disorders. Importantly, four factors have to be 
considered for a successful drug delivery to hepatocytes.  
First, the general pharmacokinetic properties of the nanoparticulate drug delivery systems 
(NDDS) have to be optimized, i.e., size, surface charge and surface modification (Figure 5). 119 
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Nanoparticles for hepatocyte-specific drug delivery have to be small enough to escape from Kupffer 
cell recognition and pass the fenestrations of liver sinusoids. 17 Nanoparticles with a size below 
150 nm are needed in order to pass the fenestrations and gain direct access to the target cell 
(i.e., hepatocytes). Furthermore, the zeta potential (i.e., surface charge) of nanoparticles has to be 
controlled. Positively charged nanoparticles have unfavorable pharmacokinetic properties. 120 Upon 
i.v. injection, these nanoparticles show a high interaction with negatively charged cell surfaces and 
thus they are quickly sequestered in the lung. 120 By contrast, nanoparticles with a high negative 
surface charge trigger the recognition by the scavenger receptor on Kupffer cells and resulting in 
phagocytic clearance. 121 Therefore, ideal hepatocyte-specific nanoparticles should have a slightly 
negative zeta potential between 0 to -10 mV. 122  
 
Another important physico-chemical characteristic, which highly influences the 
pharmacokinetic properties of nanoparticles, is the chemical composition of their surface. 
Conventional (classical) nanoparticles have no surface modification (Figure 4B). Upon i.v. injection, 
serum proteins such as complement factors attach to nanoparticles (i.e., opsonization) resulting in a 
complete change of biodistribution. 123 The reticuloendothelial system (RES, mononuclear phagocyte 
system) including the hepatic Kupffer cells and macrophages in the spleen recognize these “foreign” 
particles. 124 As a result, the nanoparticles are rapidly taken up and accumulate in the RES. This fast 
nanoparticle clearance prevents any pharmacological effect in hepatocytes and in addition enhances 
extrahepatic side effects. A solution to this problem is the concept of PEGylation (Figure 4B), 
i.e., grafting of nanoparticles with polyethylene glycol (PEG). PEGylated (stealth, long-circulating, 
sterically stabilized) nanoparticles have a hydrophilic corona which prevents opsonization. 125 This 
strategy enhances circulation half-life, and thus increases the chance to deliver drugs to the target 
cell.  
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The second factor, which is important for hepatocyte-specific drug delivery, is the target 
receptor (Figure 5A). An ideal target receptor should fulfill following criteria: abundant expression 
on cell surface (i.e., binding probability and accessibility), predominant/exclusive expression on the 
target cell type (i.e., selectivity), and efficient internalization properties (i.e., uptake into cells). 126,127 
These entire factors are important to increase the therapeutic efficacy in hepatocytes and decrease 
off-target effects on other organs and other hepatic cell types. One receptor, which fulfills all these 
criteria for hepatocyte-specific drug delivery, is the asialoglycoprotein receptor. A detailed analysis of 
the receptor properties can be found in the next section. 
 
Importantly, pathological changes (i.e., tissue alterations) within the liver during disease 
progression have to be considered. 128 These changes include (i) variations in tissue architecture, 
which influence the accessibility of the target cell type, and (ii) receptor expression alterations, which 
influence the targeting specificity. Both pathological changes might have a huge impact on the 
therapeutic outcome and concomitant side effects. First, liver damage during chronic infections or 
due to genetic diseases might alter fenestrations of liver sinusoids or change the arrangement of the 
space of Disse. For instance, elevated production of fibrotic matrix during fibrosis/cirrhosis might 
limit the extravasation of nanoparticles and therefore the delivery of sufficient concentrations to the 
side of action, i.e., hepatocytes. 44 Second, target receptor expression might decrease during disease 
progression as shown for the ASGPR in hepatocellular carcinoma. 128 Both pathological changes 
influence the targeting strategy significantly and might decrease the therapeutic benefit considerably. 
To compete with such pathological variations between different patients or within a patient’s organ, 
diagnostic tools to assess the targeting ability of nanoparticulate drug delivery systems are needed 
(i.e., prognostic factor). 129–131 The combination of therapeutic and diagnostic strategies, 
i.e., theranostics, is a promising approach to increase the success rate of targeted nanomedicines.  
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The third important factor for the development of drug targeting strategies is the targeting 
ligand (Figure 5). During the last decades, various ligands have been investigated to recognize and 
bind to parenchymal liver cells including monovalent and complex carbohydrates, glycomimetics, 
peptides, proteins or antibodies. In general, the targeting ligand and its surface density on 
nanocarriers need to be optimized for efficient binding and increased uptake. On one hand, a ligand 
with a high affinity to its target receptor should be selected resulting in efficient and specific binding 
to the target cell. On the other hand, it is crucial to optimize the ligand density on the nanoparticle 
surface. 132,133 If the ligand density is too low, the targeting ability and cell type specificity is decreased. 
By contrast, an excessive nanocarrier modification with a high ligand density might results in a 
recruitment of opsonins which could completely change the pharmacokinetic profile in favor of the 
reticuloendothelial system.  
 
The fourth factor that has to be considered for active targeting of hepatocytes is the 
availability of suitable in vitro and in vivo models (Figure 5A) to test the developed drug delivery 
technologies. Successful preclinical tests depend highly on suitable in vitro and in vivo models 
(e.g., species independence). Thus this factor might even influence the selection of the target 
receptor.  
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Figure 5: Important factors for active drug targeting using nanoparticles. (A) For active drug targeting 
using nanoparticulate drug delivery systems (NDDS) four important factors have to be considered: 
Nanocarrier, Receptor, Ligand, Model System (NRLM). (B) The physico-chemical properties of 
nanoparticulate drug delivery systems play an important role in the development of targeted 
nanomedicines. They influence the biodistribution, targeting ability and toxicity profile. Panel B is 
adapted from Bertrand et al. 134 
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Ϯ.Ϯ. ASGPR-speĐifiĐ TaƌgetiŶg 
For successful hepatocyte-specific drug delivery, the abundant and exclusive expression of a 
target receptor on the sinusoidal membrane of parenchymal liver cells is necessary. One receptor, 
which fulfills this requirement, is the asialoglycoprotein receptor (ASGPR or Ashwell-Morell 
receptor). 135,136 The following sections explain the structure of the ASGPR and its ligand specificity. 
In addition, recent approaches for ASGPR-specific drug targeting are described. 
 
 ASGPR StƌuĐtuƌe 
The hepatic ASGPR is a C-type (“calcium dependent”) lectin receptor, which specifically 
binds carbohydrates with terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues. 137–139 
Its physiological function is the clearance of desialylated glycoproteins (i.e., after removal of sialic 
acid and thus exposure of the terminal key sugars Gal or GalNAc) from circulation. 140  
The ASGPR is a hetero-oligomeric receptor complex consisting of two different subunits, 
called H1 (hepatic lectin 1, HL1) and H2 (hepatic lectin 2, HL2) (Figure 6A). Both subunits contain 
an extracellular carbohydrate recognition domain (CRD). A functional receptor is formed by 
numerous subunits with ratios of 2–5:1 (H1:H2). 141,142 Therefore, several sugars can be recognized at 
the same time. After ligand binding, the receptor is internalized within minutes by receptor-mediated 
endocytosis (clathrin-dependent pathway) (Figure 6B/C). 143,144 Approximately 500’000 ASGP 
receptors per cell are expressed by human or rodent hepatocytes in vivo. 145 This receptor density 
exceeds by orders of magnitude the expression levels in other extrahepatic regions such as the 
intestine, immune cells or kidney. These extrahepatic tissues account only for 1–5% of the total 
binding capacity. 146–148 In summary, the ASGPR is an ideal receptor for drug targeting due to its 
abundant and predominant expression on hepatocytes and the high internalization rate. 
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Figure 6: Asialoglycoprotein receptor (ASGPR) structure and endocytosis. (A) Schematic representation 
of the heterooligomeric ASGPR with carbohydrate recognition domains (CRDs) on each subunit 
(i.e., H1 and H2). The optimal geometrical conformation of multiantennary carbohydrate ligands is 
shown. (B) Receptor-mediated endocytosis via clathrin-dependent pathway after ligand binding is 
represented. Acidification of endosomes leads to separation of the ligand-receptor complex. The 
receptor recycles back to the membrane, whereas the ligand is further processed (i.e., lysosomal 
pathway). (C) Transmission electron microscopy analysis of clathrin-dependent uptake. Typical 
electron dense clathrin pits are visible. Figures are adapted from Khorev et al., Andersen et al. and 
Piccinotti et al. 149–151 
 
 ASGPR-speĐifiĐ LigaŶds 
Natural ligands of the ASGPR are glycoproteins from which the terminal sialic acid has been 
removed. These glycoproteins (e.g., asialofetuin or asialoorosomucoid) have several multiantennary 
carbohydrates with terminal galactose moieties specifically binding to the ASGPR and thus triggering 
internalization. In general, these protein-carbohydrate interactions are rather weak, with dissociation 
constants in the millimolar range. However, with increasing number of sugars binding at the same 
time to several receptor subunits, the affinity/avidity increases exponentially (tetraantennary > tri- 
>> bi ->> mono-). This enhancement of affinity due to multivalent binding is called “cluster 
glycoside effect”. 152,153 Dissociation constants of tri- or tetravalent glycans are decreased down to the 
low nanomolar range. In addition to the multivalent binding, the spatial arrangement of these 
multiantennary carbohydrates is important for specific binding. Lee et al. proposed a model 
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containing the ideal distances of terminal sugars. This model is optimal for the development of 
multiantennary ligands with a strong and specific ASGPR binding (Figure 6). 154 Notably, the 
terminal sugars play an important role for the binding. These influence the affinity significantly, 
e.g., the ASGPR has a higher affinity for GalNAc as compared to Gal (up to 60-fold). 140,155 The huge 
advantage of carbohydrate ligands for ASGPR targeting as compared to protein-based ligands is the 
species independence. The human and rodent ASGPR on hepatocytes exhibit the same carbohydrate 
recognition pattern. Therefore, in vitro results can easily be investigated in first preclinical in vivo 
experiments in rodents.  
 
 
Figure 7: Ligands for Asialoglycoprotein receptor targeting. ASGPR-targeted nanoparticles can be 
functionalized with different ligands. The targeting ability, conjugation efficiency or immunogenicity of 
these ligands have to be considered for the selection of an ideal ligand. Carbohydrate ligands are 
species independent, whereas the amino acid sequence, which is important for recognition by 
antibodies, might be species dependent. 
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 ASGPR-speĐifiĐ dƌug deliǀeƌǇ teĐhŶologies 
ASGPR-specific drug delivery technologies offer the possibility to specifically target 
hepatocytes, thereby giving access to a defined cell type within the liver. 156 Several approaches and 
different ligands for ASGPR-specific targeting have been investigated in research projects as well as 
in clinical trials (Figure 7). In general, these strategies can be divided into three groups of ligands, 
i.e., protein-based ligands (e.g., antibodies), natural and synthetic carbohydrates. 155 Antibody-based 
targeting strategies including antibody-drug conjugates (ADCs) or immunoliposomes are commonly 
used approaches to target a specific cell type. 102 Therefore, this approach has also been evaluated for 
ASGPR-specific delivery of an immunotoxin using an anti-ASGPR single-chain antibody. 157 
However, most ASGPR-specific targeting strategies are based on carbohydrate derived 
ligands. First, naturally occurring glycoproteins bearing multiantennary carbohydrates specifically 
bind to the ASGPR. Several, research groups have used these hepatotropic glycoproteins to guide 
nanomedicines specifically to parenchymal liver cells (Figure 7). 158–161 For instance, Dasi and 
colleagues mediated the gene transfer of human ơ1-antitrypsin using asialofetuin-modified lipid 
nanoparticles. 158 In addition, glycoproteins have been enzymatically digested to isolate smaller 
glycopeptides as ligands. 162 The smallest possible ligands are isolated glycans from glycoproteins, 
which still have a high binding affinity (Figure 7). The use of such natural, glycoprotein-derived 
ligands was one part of this PhD project.  
The second approach for ASGPR-specific drug targeting is the chemical synthesis of 
glycomimetics (Figure 7). Monovalent glycomimetics with dissociation constants down to 0.69 µM 
have been synthetized. 163,164 Furthermore, many attempts have been performed to develop chemical 
analogues mimicking natural multivalent sugars. 149,165–172 Either the ligand itself was synthetized in a 
multivalent form or several monovalent sugars have been attached to a nanomaterial backbone to 
obtain multivalency.  
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The most successful approaches using this multivalency have been developed in the field of 
RNA interference therapy (RNAi). Either siRNA is conjugated directly to a trivalent glycan ligand 
(siRNA-ligand conjugate, Alnylam technology, ALN) or the siRNA is combined with a pegylated 
polymer backbone (dynamic polyconjugate nanoparticles, Arrowhead Research Corporation 
technology, ARC). Both technologies are in several clinical trials for the treatment of liver disorders 
including transthyretin-mediated amyloidosis (NCT02292186, ALN-TTRsc/Revusiran) 64, hyper-
cholesterolemia (NCT02314442, ALN-PCSsc) 173, hemophilia (NCT02554773, ALN-AT3) 174, 
chronic hepatitis B virus infection (NCT02065336, ARC-520) 175, or ơ1-antitrypsin deficiency 
(NCT02363946, ARC-AAT).  
 
In conclusion, ASGPR-targeted nanomedicines, which enhance drug delivery and thereby 
decrease severe side effects associated with conventional medicines, offer promising therapeutic 
options and have the potential to overcome the striking limitations of existing, conventional drugs. 
 
III. Gene Delivery 
Gene therapy is one of the most important directions for the treatment of genetic liver 
disorders. 176 However, the translation from bench-to-bedside remains a major hurdle for most 
nucleic acid delivery systems since there is a lack of efficient and safe carrier systems. So far, only 
3.7% of all clinical trials involving gene therapy reached a late clinical phase. 177 These delivery 
strategies were mostly based on the use of viral vectors. The low success rate of these studies can 
therefore be attributed to limitations of viral systems with respect to immunogenicity and generalized 
toxicity. 178 As an alternative, non-viral gene delivery systems are an interesting and safe option, 
which offer several advantages. 102 Ongoing research projects on RNAi therapeutics using non-viral 
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carriers are at present one of the most important directions in the treatment of hepatic disorders.  
Several companies have initiated research programs and first clinical trials. 179–181 The ligand 
conjugated and stabilized siRNA constructs used in these studies were designed to efficiently transfer 
small nucleoside analogues (size of 21–23 bp) into cells to knock down the gene of interest. 182–184 
However, the induced pharmacological effects obtained by this siRNA-based strategy are short-lived, 
i.e., in the range of days in contrast to weeks for gene delivery using a DNA expression plasmid. 185 
For example, long-term silencing of Intersectin-1 (a protein regulating the mitochondrial apoptotic 
pathway in endothelial cells) in the lung necessitated repeated intravenous administration (every 72 
hours, for 24 consecutive days) of siRNA/cationic liposome complexes. 186 Therefore, the gene 
delivery of expression plasmids is the favorable option for long-term therapeutic effects.  
 
1. Plasmid DNA Delivery 
Plasmid DNA (pDNA) delivery strategies are based on the use of nanocarriers, which are 
loaded with a plasmid DNA of interest (e.g., an expression plasmid) (Figure 8). Such delivery systems 
can accommodate large pDNA polynucleotides with a size of up to 8 kilo bp. It is thus possible to 
both transfer a gene of interest (“gene delivery” including “knock-in” strategies) leading to the 
expression of a functional protein or to “knock-down” target genes by gene silencing using DNA-
directed RNA interference (ddRNAi). For successful delivery of pDNA and subsequent expression 
of the encoded, exogenous protein several hurdles have to be overcome: (I) efficient nucleic acid 
packaging, (II) long plasma circulation, (III) extravasation from sinusoids, (IV) cellular uptake by 
endocytosis, (V) endosomal escape, (VI) intracellular pDNA release, and (VII) nucleus entry. 104  
To address the major challenge of endosomal escape, specific technologies such as pH 
responsive systems, pore forming agents, or fusogenic compounds can be used (Figure 8). 187–189 In 
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the case of the pH buffering effect (i.e., proton sponge effect) ionizable groups of the nanocarrier are 
protonated during the endo-lysosomal pathway. Thus, the acidification of endosomes is 
counterbalanced which enhances the action of ATPase enzyme pumps. Finally, the increased 
intraendosomal ion concentration results in osmotic swelling and endosomal burst.  
 
 
 
Figure 8: Hurdles for plasmid DNA delivery iŶ ǀiǀo. (1) Stable plasmid DNA loaded nanoparticles are 
formed. (2) After injection, the stealth gene delivery system circulates in the blood. (3) After passage 
of fenestrated sinusoids, (4) the targeted nanoparticles specifically bind to hepatocytes. Subsequently, 
the cellular uptake of pDNA-nanoparticles is triggered. (5) After endosomal escape, (6) the pDNA is 
released from the nanocarrier into the cytoplasm. (7) Nuclear trafficking results in (8) transcription of 
the gene. (9) Finally, the mRNA is transported into the cytoplasm, where the exogenous protein is 
translated. (10) Further processing results in a mature protein, which performs its function inside the 
cell or in circulation iŶ ǀiǀo. 
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ϭ.ϭ. Taƌgeted GeŶe DeliǀeƌǇ 
For the design of targeted nanoparticles, established and safe delivery systems should be used 
such as sterically stabilized liposomal drug carriers. Thus, a systemic administration of pDNA is 
possible. Coupled targeting ligands promote tissue-specific nucleic acid delivery. Advantages of such 
targeted nanoparticulate gene delivery systems can be summarized as follows:  
First, the cargo is protected from metabolic degradation since it is enclosed within a 
nanoparticle. In particular, DNA expression plasmids need to be protected to avoid degradation by 
plasma derived nucleases. Second, the system is versatile in that different types of molecules can be 
loaded into nanocarriers, including peptides, polynucleotides, fluorescent markers or small drug 
molecules. Thus, diagnostic technologies can be combined with therapeutic drug delivery 
(i.e., theranostics).  
Third, the targeting efficiency of the targeting ligand is increased since a limited number of 
such ligands are needed to direct a nanoparticle loaded with several nucleic acid molecules to a target 
tissue. This approach is more efficient than direct coupling of a single drug molecule to a single 
targeting vector. 102 Fourth, the technology can be considered as a modular platform technology 
where different components can be readily combined and exchanged. Target specificity and 
pharmacokinetics of the nanocarriers are solely a function of the used targeting vector and the 
physico-chemical properties. They are not influenced by the transported cargo. Targeting specificity 
can be adjusted by a simple exchange of the targeting vector or variation of its density. Fifth, the host 
system is protected from the cargo reducing the risk of unwanted immunological reactions.  
 
In conclusion, the most important key factors for the design of gene delivery systems are the 
combination of efficient and targeted nucleic acid delivery with low cytotoxicity, cellular uptake, 
intracellular release and transcription of pDNA (Figure 8).  
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AIM OF THE THESIS 
As outlined above, conventional therapeutics for the treatment of hepatocyte-related diseases 
are often insufficient. For many incurable or late-stage liver disorders, liver transplantation still is the 
only available treatment option. Hepatocyte-specific targeting technologies represent a promising 
therapeutic strategy to overcome the limits of conventional drugs in the treatment of cancer, 
infections, or genetic diseases. Therefore, the aim of this PhD thesis was the development of drug 
delivery and targeting strategies for hepatocyte-related disorders and the implementation of imaging 
and gene delivery technologies. To achieve these objectives several factors had to be explored: 
 
  Evaluation of nanoparticulate drug delivery technologies 
 Which nanomaterials are used in clinical applications? 
 Which nanomaterials have stealth properties? 
 
  Evaluation of hepatocyte-specific targeting strategies 
 Which receptors are specific for hepatocytes? 
 Which targeting strategies have already been evaluated? 
 
  Investigation of selected target receptor  
 What is the receptor expression in health or disease? 
 Are there suitable in vitro/in vivo models available? 
 
  Assessment of targeting ligands 
 Which targeting ligands can be used? 
 What advantages/disadvantages do these ligands have? 
 
  Development of imaging technologies to analyze uptake mechanisms 
 Which imaging methods can be used? 
 How can the intracellular fate of nanocarriers be visualized? 
 
  Exploration of novel nanomaterials for gene delivery 
 What are important factors for gene delivery? 
 Is it possible to use stealth nanomaterials for gene delivery? 
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Chapter I  
“Nanomedicine in Cancer Therapy: Challenges, 
Opportunities, and Clinical Applications” 
 
WitzigŵaŶŶ D*, WiĐki A*, BalasuďƌaŵaŶiaŶ V, HuǁǇleƌ J. 
Journal of Controlled Release. 2015 Feb 28; 200:138-57.  
doi: 10.1016/j.jconrel.2014.12.030. (*ĐoŶtƌiďuted eƋuallǇͿ 
http://www.sciencedirect.com/science/article/pii/S016836591400827X 
 
Highlights: Nanomedicine therapeutics represent an opportunity to achieve sophisticated targeting 
strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic 
profiles of conventional therapeutics and thus optimize the efficacy of existing anti-cancer 
compounds. This review article highlights advances in the field of nano-delivered anti-cancer drugs. 
In particular, a comprehensive overview of ongoing and completed clinical trials is provided. State-
of-the-art drug conjugates and nanocarriers are described. Challenges faced in using nanomedicine 
products and translating them from experimental conditions to the clinical setting are emphasized, 
i.e., complex physico-chemical features, safety concerns, and regulatory as well as manufacturing 
issues. In addition, aspects of nanoparticle engineering that may open up new opportunities for next-
generation nanomedicine products in the clinic are covered. 
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Chapter II  
“Polymeric Nanomaterials: Applications in 
Therapeutics” 
 
WitzigŵaŶŶ D, CaŵďliŶ M, HuǁǇleƌ J, BalasuďƌaŵaŶiaŶ V. 
Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, 1st Ed.; 
Mishra, M. 2015; Vol. 8, p. 5364-78. 
 
 
 
 
Highlights: During the last decades, intensive efforts have been made to develop new types of 
nanomaterials for biomedical applications. Polymers that spontaneously self-assemble in aqueous 
solution into various nanoscale structures such as micelles, nanoparticles, and vesicles have a huge 
potential to serve as nanocarriers for various therapeutic applications. This review article highlights 
the fundamental and physicochemical properties of self-assembled morphologies like micelles, 
polymeric nanoparticles, vesicles (polymersomes), and layer-by-layer capsules. Formulation 
characteristics such as loading efficiency, stability, and release properties of polymeric nanocarrier 
systems are covered. Biological properties of the polymeric nanomaterials and their therapeutic 
applications from the delivery of small drug molecules to proteins and gene delivery are emphasized. 
Results - Chapter II 
 
using active targeted nanomedicines”  63 
Results - Chapter II 
 
64   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  65 
Results - Chapter II 
 
66   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  67 
Results - Chapter II 
 
68   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  69 
Results - Chapter II 
 
70   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  71 
Results - Chapter II 
 
72   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  73 
Results - Chapter II 
 
74   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  75 
Results - Chapter II 
 
76   “Hepatocyte-specific drug delivery 
Results - Chapter II 
 
using active targeted nanomedicines”  77 
 
Results - Chapter III 
 
78   “Hepatocyte-specific drug delivery 
Chapter III  
“Variable Asialoglycoprotein Receptor 1 
Expression in Liver Disease: Implications for 
Therapeutic Intervention” 
 
WitzigŵaŶŶ D, Quagliata L, SĐheŶk SH, QuiŶtaǀalle C, TeƌƌaĐĐiaŶo LM, 
HuǁǇleƌ J. 
Hepatology Research. 2015 Sep 30. doi: 10.1111/hepr.12599. 
http://onlinelibrary.wiley.com/doi/10.1111/hepr.12599/abstract 
 
Highlights: For a successful clinical outcome of hepatocyte-targeted drug delivery systems it is 
important to carefully consider the asialoglycoprotein receptor 1 (ASGR1) expression level and 
expression pattern. In this study, the ASGR1 expression was analyzed at the mRNA and protein 
level using various liver cancer-derived cell lines as well as human tissue specimens, from both 
normal and pathological liver. Several analytical techniques including RT-PCR, flow cytometry, 
confocal microscopy, RNA microarray, and immunohistochemistry were used. The analysis revealed 
an altered ASGR1 expression level in cirrhotic specimens or hepatocellular carcinoma. In the future, 
this study will be instrumental for the development of ASGPR-targeted nanomedicines and 
companion diagnostics in order to translate targeted nanomedicines from basic research to the clinic. 
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Chapter IV  
“Hepatocyte Targeting Using Pegylated 
Asialofetuin-Conjugated Liposomes” 
 
Detaŵpel P, WitzigŵaŶŶ D, KƌäheŶďühl S, HuǁǇleƌ J. 
Journal of Drug Targeting. 2013 Dec 13; 22(3):232-41.  
doi: 10.3109/1061186X.2013.860982 
http://www.tandfonline.com/doi/abs/10.3109/1061186X.2013.860982?j
ournalCode=idrt20 
 
Highlights: Active drug targeting to parenchymal liver cells improves therapeutic efficacy in the 
liver and reduces side effects in non-diseased tissues such as the spleen. This study aimed to develop 
a hepatocyte-specific drug delivery strategy using pegylated liposomes modified with asialofetuin. 
Active targeting of the hepatic asialoglycoprotein receptor (ASGPR) and internalization via receptor-
mediated endocytosis was studied in vitro and confirmed in vivo in the rat. Different types of 
encapsulated model compounds, including membrane-linked fluorochromes and quantum dots, were 
used to demonstrate the feasibility of the targeting strategy. This study is the first successful attempt 
to target the hepatic ASGPR with ligand-conjugated, pegylated liposomes. This approach might be 
instrumental to implement novel drug targeting strategies for the treatment of hepatic diseases.  
Results - Chapter IV 
 
using active targeted nanomedicines”  99 
Results - Chapter IV 
 
100   “Hepatocyte-specific drug delivery 
Results - Chapter IV 
 
using active targeted nanomedicines”  101 
Results - Chapter IV 
 
102   “Hepatocyte-specific drug delivery 
Results - Chapter IV 
 
using active targeted nanomedicines”  103 
Results - Chapter IV 
 
104   “Hepatocyte-specific drug delivery 
Results - Chapter IV 
 
using active targeted nanomedicines”  105 
Results - Chapter IV 
 
106   “Hepatocyte-specific drug delivery 
Results - Chapter IV 
 
using active targeted nanomedicines”  107 
Results - Chapter IV 
 
108   “Hepatocyte-specific drug delivery 
 
Results - Chapter V 
 
using active targeted nanomedicines”  109 
Chapter V  
“Isolation of Multiantennary N-Glycans from 
Glycoproteins for Hepatocyte specific Targeting 
via the Asialoglycoprotein Receptor” 
 
WitzigŵaŶŶ D, Detaŵpel P, Poƌta F, HuǁǇleƌ J. 
RSC Advances. 2016 Oct 07; 2016, 6, 97636-97640.                                            
doi: 10.1039/C6RA18297F 
http://pubs.rsc.org/en/content/articlelanding/2016/ra/c6ra18297f#!divA
bstract 
 
Highlights: Complex multivalent carbohydrates from glycoproteins offer a huge potential to 
specifically target parenchymal liver cells via the asialoglycoprotein receptor (ASGPR). Natural 
N-glycans are expected to be superior to multivalent glycomimetics with respect to ease of 
preparation, geometrical arrangement of the antennary carbohydrates, and biocompatible properties. 
In this study, an enzymatic isolation strategy for multiantennary, desialylated asparagine-linked 
carbohydrates from fetuin followed by conjugation to a fluorescent dye using reductive amination is 
described. These glycan-conjugates were successfully used to actively target the ASGPR on human 
hepatocellular carcinoma cells in vitro. In the future, isolated N-glycans might be ideal candidates for 
further development of ASGPR targeting strategies to guide drugs to the key pathogenic cell type 
and mediate endocytosis into parenchymal liver cells. 
Results - Chapter V 
 
110   “Hepatocyte-specific drug delivery 
Results - Chapter V 
 
using active targeted nanomedicines”  111 
Results - Chapter V 
 
112   “Hepatocyte-specific drug delivery 
Results - Chapter V 
 
using active targeted nanomedicines”  113 
Results - Chapter V 
 
114   “Hepatocyte-specific drug delivery 
Results - Chapter V 
 
using active targeted nanomedicines”  115 
Results - Chapter V 
 
116   “Hepatocyte-specific drug delivery 
Results - Chapter V 
 
using active targeted nanomedicines”  117 
Results - Chapter V 
 
118   “Hepatocyte-specific drug delivery 
Results - Chapter V 
 
using active targeted nanomedicines”  119 
Results - Chapter V 
 
120   “Hepatocyte-specific drug delivery 
Results - Chapter V 
 
using active targeted nanomedicines”  121 
 
Results - Chapter VI 
 
122   “Hepatocyte-specific drug delivery 
Chapter VI  
“Formation of Lipid and Polymer-based Gold 
Nanohybrids Using a Nanoreactor Approach” 
 
WitzigŵaŶŶ D, Sieďeƌ S, Poƌta F, GƌosseŶ P, Bieƌi A, StƌelŶikoǀa N, Pfohl T, 
BasĐhoŶg C, HuǁǇleƌ J. 
RSC Advances. 2015 Aug 25; 5(91):74320-28. doi: 10.1039/c5ra13967h 
http://pubs.rsc.org/en/Content/ArticleLanding/2015/RA/C5RA13967H#!
divAbstract 
 
Highlights: The analysis of nanocarrier uptake and their intracellular fate is of great interest in 
biomedical research. Bioimaging tools to determine subcellular localization of nanocarriers are 
increasingly needed. This publication highlights the development of a novel and versatile strategy to 
encapsulate gold nanoparticles into nanocarriers. This approach is applicable to different 
nanomaterials as well as various preparation techniques with high reproducibility. The unique optical 
properties of gold loaded nanocarriers were used to visualize cellular uptake in vitro demonstrating 
the promising applicability as a bioimaging tool for intracellular trafficking. In the future, this 
technology will be instrumental to develop a better understanding of the complex cellular uptake 
processes and intracellular trafficking of nanocarriers. 
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Chapter VII  
“Biocompatible Polymer-Peptide Hybrid-Based 
DNA Nanoparticles for Gene Delivery” 
 
WitzigŵaŶŶ D*, Wu D*, SĐheŶk SH, BalasuďƌaŵaŶiaŶ V, Meieƌ W, 
HuǁǇleƌ J. 
ACS Appl Mater Interfaces. 2015 May 20; 7(19):10446-56.  
doi: 10.1021/acsami.5b01684. (*ĐoŶtƌiďuted eƋuallǇͿ 
http://pubs.acs.org/doi/abs/10.1021/acsami.5b01684 
 
Highlights: The delivery of nucleic acids is one of the most interesting areas in nanomedicine 
research. In this publication, the development of a novel polymer-peptide hybrid system for gene 
delivery is highlighted. A biocompatible and protein repellent synthetic polymer (i.e., PMOXA) was 
combined with a biocleavable peptide block, namely PASP. This polymer-peptide hybrid system was 
modified with diethylenetriamine to allow for plasmid DNA complexation and delivery. Transfection 
of target cells was achieved in vitro with high efficiency. PMOXA-b-PASP(DET) nanoparticles had a 
slightly negative zeta potential and were not cytotoxic. These unique properties set this block 
copolymer apart from established polycationic DNA delivery systems. In the future, this versatile 
and biocompatible polymer might find a widespread use in the field of targeted gene therapy. 
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DISCUSSION AND CONCLUSION 
In the context of this PhD thesis on “Hepatocyte-specific drug delivery using active targeted 
nanomedicines” various drug delivery and drug targeting strategies to parenchymal liver cells were 
developed. This “Discussion and Conclusion” paragraph brings all research achievements into a 
larger context. Active targeting strategies are summarized and new targets are evaluated. In addition, 
the development of a gene delivery system is elaborated. 
 
I.  Active Targeting Strategy And Its Analysis 
1. Hepatocyte-specific Drug Targeting 
ϭ.ϭ. IŵpoƌtaŶĐe of TaƌgetiŶg AppƌoaĐh 
(i) The liver is characterized by a high metabolic rate, (ii) many drugs and nanoparticles 
passively accumulate in the liver, (iii) and liver parenchymal cells represent approximately 80% of all 
hepatic cells. These statements can lead to a misconception and thus raise the question why 
hepatocyte-specific targeting approaches are needed. The answer can be found in the biodistribution 
and subsequent drug accumulation. Most conventional drugs and nanoparticles do not accumulate in 
the correct cell type. Mostly, they passively accumulate in tissue-resident Kupffer cells. These 
members of the mononuclear phagocyte system comprise more than 80% of the total population of 
macrophages in the body and lead to a fast clearance of administered therapeutics. Active targeting 
strategies are the prerequisite to decrease the exposure of non-diseased cells and at the same time 
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reach sufficient concentrations at the side of action (i.e., inside the key pathogenic cell type). 
Therefore, drug targeting of parenchymal liver cells not only includes organ-specific targeting 
(i.e., liver), but also avoidance of tissue-resident macrophages, and distinction between different 
hepatic cell types. Avoidance of Kupffer cells is essential to prevent unspecific and rapid 
accumulation of nanoparticles in the liver and other tissues characterized by a high activity of the 
mononuclear phagocyte system (e.g., spleen). Therefore, nanocarriers have to be modified with a 
hydrophilic polymer (i.e., PEG or PMOXA) in order to prevent opsonization in vivo. Active targeting 
ligands are necessary to guide the nanocarrier to the correct cell type (i.e., hepatocytes) and trigger 
endocytosis. In particular, this is obligatory for compounds which pharmacological effect depends on 
internalization, such as nucleic acid therapeutics.  
During this PhD project, different ligands were evaluated and various hepatocyte-targeted 
drug delivery systems were successfully tested in vitro as well as in vivo. These optimally designed 
hepatocyte-specific targeting technologies might be promising alternatives to conventional 
therapeutics. 
 
2. ASGPR-specific Targeting 
Ϯ.ϭ. Taƌget ReĐeptoƌ 
For hepatocyte-specific drug targeting, the abundant and exclusive expression of a target 
receptor on the surface of parenchymal liver cells is necessary. In this PhD project, the ASGPR was 
successfully evaluated (Chapter III) for the development of active targeted nanocarriers. In healthy 
tissue specimens, the ASGPR is abundantly expressed on the sinusoidal membrane of parenchymal 
liver cells. Hence, the ASGPR-specific drug targeting strategy can be used for patients without 
parenchymal damage (Table 2). By contrast, the ASGPR expression is decreased with increasing 
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HCC grade. Interestingly, the ASGPR is upregulated in cirrhotic tissue. This might be interesting for 
an early treatment option of chronic liver infections. However, the pathological changes including 
enhanced fibrotic matrix deposition in the space of Disse might decrease the targeting ability. 
Diagnostic tools to assess the targeting ability of parenchymal liver cells in different patients offer a 
promising approach. Thus, a preselection of responders could help to enhance the clinical outcome.  
 
Ϯ.Ϯ. ASGPR-speĐifiĐ LigaŶds 
Hepatocyte-specific drug delivery via the ASGPR can be achieved using glycan-derived 
targeting ligands (i.e., glycoproteins, multiantennary carbohydrates, or monovalent sugars) as well as 
antibodies against the ASGPR (Figure 7). During this PhD project, several different targeting ligands 
were evaluated. Table 3 summarizes the advantages and disadvantages of these approaches.  
Firstly, a glycoprotein (i.e., bovine asialofetuin) which contains various multiantennary 
N-glycans was successfully used to guide stealth liposomes specifically to hepatocytes (Chapter IV). 
In order to overcome the main disadvantage of bovine asialofetuin, immunogenicity, either the 
human analogue or isolated N-glycans should be used. The latter approach was investigated in vitro to 
specifically trigger the internalization into hepatocytes (Chapter V). The use of these multivalent 
glycan ligands might be a promising and efficacious strategy in vivo. The main advantages are the high 
affinity, enhanced specificity, small size and biocompatibility.  
In addition, to the targeting ligands explicitly described and discussed in the “Results” 
section, various other targeting approaches were assessed during this PhD project. The use of 
synthetic ligands including multiantennary glycan conjugates or monovalent glycomimetics was 
considered. Ernst and colleagues synthesized several different high affinity ligands. 149,164 However, 
the availability of sufficient amounts needed for the development of nanoparticulate drug delivery 
systems was restricted due to the complex chemical synthesis. 
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Table 3: Expert opinion on ASGPR-specific targeting ligands. The advantages and disadvantages of 
different ligands for ASGPR-specific drug targeting are summarized. Synthetic glycans, natural glycans 
and protein-based ligands are evaluated separately. In each group the complexity and ASGPR affinity 
of ligands decreases from top to bottom.  
 
Ligand Type 
 
Advantages Disadvantages Ref. 
 
Synthetic Glycan Ligands    
 Multivalent Glycans high affinity, chemical 
variability 
expensive, complex synthesis, 
sub-optimal geometrical 
arrangement, availability  
 
149,167,169 
 Monovalent Glycans medium affinity, chemically 
defined 
 
expensive, lower affinity 163,164 
 
Natural Glycan Ligands    
 Glycoproteins (e.g., asialofetuin) highest affinity (several 
multivalent glycans), cheap, 
high amount 
 
immunogenic, batch-to-batch 
differences  
103,158,159 
 Glycopeptides  high affinity, lower 
immunogenicity 
 
glycan variability, several 
production steps necessary 
162 
 Multivalent Glycans (e.g., NA3) high affinity, no synthesis, ideal 
geometrical arrangement  
isolation necessary, yield low, 
reproducibility/quality 
dependent on starting material 
 
 
 Monovalent Glycans (e.g., GalNAc) cheap, easy to use, 
improvement of avidity using 
surface of nanocarriers 
low affinity/specificity, density 
on nanocarriers influences 
outcome 
165,166,168 
 
Protein-based Ligands    
 Antibodies high specificity species dependent, 
immunogenic, expensive 
157,190 
 
 
 
An alternative strategy to mimic multivalency of natural N-glycans is the conjugation of 
monovalent sugars onto the surface of nanocarriers. This approach has also been evaluated during 
this PhD project using stealth liposomes. Based on the fluidity of the lipid bilayer, ligands conjugated 
to a lipid bilayer-standing anchor (i.e., DSPE-PEG2000) should self-assemble in clusters and 
therefore mimic a multivalent ligand. 191 Custom synthesized monovalent GalNAc moieties 
(i.e., Ƣ-GalNAc-PEG2-SH) were conjugated to the surface of pegylated liposomes to increase their 
specificity and avidity, and thus enhance the uptake rate in hepatocytes.  
However, cellular uptake experiments showed no difference in uptake rate of 
GalNAc-conjugated liposomes as compared to stealth liposomes. The absent targeting ability can be 
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attributed to the amount of sugar moieties needed to exactly mimic the optimal spatial arrangement 
of multiantennary glycans. To reach the ideal geometrical distance of sugar moieties, up to 20mol% 
of DSPE-PEG would be necessary. Already starting at 10mol% we observed the formation of 
micelles (electron microscopy analysis). Therefore, the optimal concentration of ligands on the 
nanocarrier surface cannot be achieved. Furthermore, the influence on biodistribution for future 
in vivo applications has to be considered. A high rate of modification might interact with stealth 
properties and cell type specificity in vivo. Shimada and colleagues showed that 20mol% 
galactosylated lipids significantly increased the uptake rate in Kupffer cells at the expense of 
parenchymal liver cells. 168  
 
Finally, the use of antibodies for ASGPR-specific drug targeting was evaluated. Several 
research projects from our group have successfully shown that antibodies can be used to guide 
liposomal drug delivery systems to specific tissues. 192–196 In terms of immunogenicity, single-chain 
antibody fragments (scFv) are advantageous for in vivo applications as compared to full-length 
antibodies. Recently, Trahtenherts and colleagues isolated a scFv against the ASGPR from a phage 
display library to facilitate the internalization of a highly effective immunotoxin. 157 Therefore, this 
targeting ligand was investigated for nanoparticulate drug delivery. However, preliminary 
experiments showed that the applicability as a ligand for nanocarriers was limited. Due to its low 
affinity, further investigations using this scFv were not performed.  
 
In conclusion, pegylated liposomes for ASGPR-specific targeting should be combined with 
glycoproteins or multiantennary glycans. These approaches were successfully tested during this PhD 
project in vitro as well as in vivo. Alternatively, other receptors for hepatocyte-specific targeting 
approaches should be evaluated in the future (see below and exemplified in the “Future Perspective” 
section). 
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3. Alternative Targeting Approaches 
Since the ASGPR is significantly downregulated in some pathological liver diseases such as 
hepatocellular carcinoma, other surface proteins on hepatocytes should be evaluated in the future. 
Interestingly, viruses also use active targeting approaches to enter parenchymal liver cells. The 
following paragraph summarizes three receptors interesting for the development of active targeted 
nanomedicine therapeutics, which are also used by viruses to enter hepatocytes.  
 
First, the low-density lipoprotein receptor (LDLR) is highly expressed on hepatocytes. 
Natural ligands such as apolipoprotein E (ApoE) are internalized after receptor binding. 
Interestingly, this receptor (among several others) is utilized by the hepatitis C virus as an entry 
pathway. 197,198 During the last decade, this strategy has also been evaluated for nanoparticulate drug 
delivery systems. Akinc and colleagues showed in vivo that siRNA loaded lipid nanoparticles 
spontaneously absorb ApoE on their surface after systemic administration. 182 This allows specific 
binding of the “endogenous ligand-modified nanocarriers” to the hepatic LDL receptor and 
mediation of cellular uptake. Interestingly, this technology is already in clinical trials for the therapy 
of genetic liver diseases. 65 Patisiran is tested in a phase 3 clinical trial for the treatment of 
transthyretin-mediated amyloidosis (NCT 01960348, ALN-TTR02). However, the LDLR is not 
exclusively expressed on hepatocytes. Targeting strategies to pass the blood-brain-barrier also take 
advantage of this approach. 199–201 Therefore, the specificity of LDL-targeted nanocarriers is limited 
and off-target effects have to be kept in mind.  
 
Second, the coxsackie-adenovirus receptor (CAR) on hepatocytes is utilized by 
adenoviruses to accumulate in parenchymal liver cells. 100 This approach has been evaluated for viral 
gene therapy approaches. 202,203 However, safety concerns due to immunogenicity, gene transduction, 
and off-target effects prevent the widespread use. 204,205 
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Third, the sodium-taurocholate cotransporting polypeptide (NTCP/SLC10A1) on 
parenchymal liver cells might be an interesting target. The hepatitis B virus has a strong affinity to 
hepatocytes. However, for a long time the exact mechanism of this highly efficient hepatotropism 
was unknown. Recently, Yan and colleagues discovered that the human hepatitis B virus binds with 
high affinity to the hNTCP. 85 To specify the exact requirements for this strong binding, Urban et al. 
performed a fine mapping of the HBV surface protein (HBVpreS) sequence. 206 This approach 
revealed a highly essential peptide sequence (NPLGFFP) in the HBV envelope proteins specific for 
the hNTCP. 84 The discovery resulted in the first HBV/HDV entry inhibitor (IC50 = 80 pM), namely 
Mycludex B. 207 
 
The development of a novel nanoparticulate drug targeting approach to the human NTCP 
and its implementation is carefully elaborated in the “Future Perspective” section as an alternative to 
ASGPR-specific targeting strategies. 
 
 
II. Gene Delivery 
Nanoparticulate drug delivery systems offer the unique opportunity to transport complex 
biomolecules including nucleic acids. Therefore, it is possible to implement gene therapy approaches 
for systemic administration. During this PhD project the feasibility of such an approach was 
evaluated and a stealth polymeric nanomaterial was tested in vitro. This “Discussion and Conclusion” 
section elaborates the use of non-targeted gene delivery systems including commercially available 
transfection reagents and the developed sterically stabilized plasmid DNA nanocarrier. In addition, 
further improvements necessary for a targeted gene delivery in vivo are emphasized.  
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1. Passive Gene Delivery 
ϭ.ϭ. TƌaŶsfeĐtioŶ ReageŶts 
Commercially available transfection reagents such as Lipofectamine 2000, FuGene HD, or 
jetPEI profit from high transfection efficiencies in vitro. These positively charged lipid or polymer 
mixtures electrostatically interact with negatively charged nucleic acids, thus forming cationic lipo- or 
polyplexes. The positive surface charge enhances the interaction with negatively charged cell 
membranes, thus enhancing cellular uptake. Intracellularly, the nucleic acid-nanocarrier complexes 
are released via endosomal escape mechanisms and thus allow for gene expression.  
In particular, for in vitro experiments these transfection reagents are favorable. However, they 
suffer from major drawbacks. First, the high positive charge of the complexes results in increased 
cytotoxicity. Second, the in vivo application is limited. After systemic administration positive 
complexes are rapidly sequestered in the lung. Therefore, only a local administration such as 
intratumoral injection is possible thereby decreasing patient compliance and acceptance. 
 
ϭ.Ϯ. AdǀaŶĐed TƌaŶsfeĐtioŶ ReageŶt 
An advanced transfection reagent would offer possibilities to complex nucleic acids during 
formulation (low pH) and result in a neutral or negative surface charge at physiological pH 
(pH = 7.4). In addition, advanced gene delivery systems should be sterically stabilized. This would 
offer possibilities to envision a systemic administration.  
During this PhD project, a novel, biocompatible, and stealth polymer-peptide hybrid 
nanomaterial was developed. The general physico-chemical properties of the resulting pDNA-
polymer nanoparticles are ideal for the development of a hepatocyte-directed gene therapy. The 
nanoparticle size was less than 120 nm, they had a monodisperse size distribution and a slightly 
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negative zeta potential. Importantly, passive transfection of cells in vitro was achieved without 
cytotoxic drawbacks. In order to increase the transfection efficiency further modification is 
necessary.  
First, targeting ligands attached to the surface of these nanocarriers might increase cellular 
uptake and thus gene delivery. Second, the nanomaterial should be optimized in regard to pDNA 
encapsulation and efficient intracellular release. The development of novel lipid-based nanomaterials 
is described in the “Future Perspective” section. 
 
2. Active Targeted Gene Delivery 
The pharmacological effect of nucleic acids (i.e., plasmid DNA, mRNA, siRNA, miRNA) is 
dependent on internalization. In order to facilitate the uptake of negatively charged nucleic acids 
across the negatively charged cell membrane, nanoparticulate delivery systems are necessary. As 
mentioned above, neutral or slightly negative nanocarriers are needed for systemic application. 
However, this hampers the uptake of nanocarriers. Therefore, targeting ligands are required to guide 
the nanocarriers to a defined cell type and enhance cellular uptake (Figure 8). During this PhD 
project, several targeting ligands were evaluated. This knowledge should be used in the future to 
develop a hepatocyte-specific gene delivery system.  
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III. Conclusion 
Despite the improved therapeutic options for many diseases, incidence rates of hepatic 
disorders are further increasing and millions of people are affected around the globe. In the context 
of this PhD thesis, drug delivery and drug targeting strategies to parenchymal liver cells should be 
evaluated and developed.  
 
During this PhD project the four core aspects of hepatocyte-specific drug delivery were 
evaluated: (i) nanocarrier systems, (ii) target receptors, (iii) targeting ligands, (iv) in vitro/in vivo 
models. First, various nanomaterials and drug delivery systems were evaluated regarding their clinical 
application (Chapter I/II). Several stealth nanoparticulate drug delivery systems were developed 
accordingly. Second, the use of the ASGPR as target receptor for hepatocyte-specific drug delivery 
was assessed. ASGR1 expression levels in human liver specimens and several liver-derived cell lines 
were investigated (Chapter III). Third, various ASGPR-specific targeting ligands were evaluated. 
Glycoproteins and glycans were tested for their targeting ability and ASGPR-specificity in vitro as well 
as in vivo (Chapter IV/V). Furthermore, technologies to investigate the uptake mechanisms and 
intracellular fate of nanocarriers were established (Chapter VI). Fourth, all in vitro and in vivo tests 
were performed in suitable model systems (Chapter III/IV/V). Finally, the first steps towards the 
development of a hepatocyte-specific gene delivery system were made (Chapter VII).  
 
In conclusion, future projects should use the acquired technologies for the development of 
novel hepatocyte-targeted gene delivery systems. This is of great interest for therapeutic 
interventions of various liver disorders. The idea and concept of a possible research project is 
described in detail in the “Future Perspectives” section. 
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FUTURE PERSPECTIVES  
Nanomedicines for the delivery of therapeutic genes have the potential to overcome the lack 
of satisfactory and alternative treatment options for hepatic disorders. Therefore, future projects 
should focus on the design of functional nanomedicines for targeted nucleic acid delivery to liver 
parenchymal cells.  
To implement such targeting strategies, the following steps are necessary: (I) Identification of 
an alternative, highly selective and specific targeting ligand, (II) development of novel ionizable 
nanomaterials to assist in the formulation of expression plasmids, (III) combination of targeting 
strategy and gene delivery technology to address unmet medical needs in vivo. 
 
I. Novel Targeting Strategy  
So far, hepatocyte-specific targeting strategies have been based on ASGPR-specific drug 
carriers. However, as outlined in this PhD thesis, the ASGPR showed variable expression levels and 
altered expression patterns in different patients as well as different liver disorders. In addition, 
targeting vectors based on “asialofetuin” have important shortcomings including batch-to-batch 
differences and possible immunogenicity. In view of these problems, alternative hepatocyte-specific 
targeting strategies should be evaluated.  
The most promising target to implement such an approach is the sodium/bile acid 
cotransporter hNTCP (sodium-taurocholate cotransporting polypeptide), which is highly expressed 
on parenchymal liver cells. 
Future Perspectives  
 
162   “Hepatocyte-specific drug delivery 
1. Active Targeting of hNTCP 
In close collaboration with the Molecular Virology Division at the University of Heidelberg 
(Group of Prof. Dr. Stephan Urban), a novel hepatitis B virus (HBV) entry inhibitor should be tested 
as targeting ligand. The HBV entry inhibitor Myrcludex B was developed by Urban and colleagues 
and is at present being tested in clinical phase IIa studies (NCT02637999). Interestingly, Myrcludex B 
is characterized by a strong tropism towards hepatocytes. The polypeptide-lipid conjugate binds with 
high affinity to the hNTCP thereby effectively blocking HBV entry and infection (Figure 9). 
Myrcludex B is a lipid-conjugated polypeptide identified by epitope mapping of the preS1 domain of 
the N-terminal extension of the large surface glycoprotein of HBV (Figure 9).  
 
 
Figure 9: Hepatitis B Virus (HBV) structure and cell entry. (A) Structure of HBV with envelope consisting 
of different surface proteins. Important for hepatocyte-specific binding is the myristoylated preS1 
domain. Myrcludex B is the first HBV entry inhibitor blocking the hNTCP tested in clinical trials. 
(B) Route of hepatocyte uptake is shown. The HBV passes the hepatic sinusoids to enter the space of 
Disse, where it interacts with proteoglycans. The specific binding to the NTCP results in endocytosis. 
Intracellular processes are initiated for the replication inside hepatocytes. Figures are adapted from 
Urban et al. 88 
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In order to implement a novel targeting strategy to hepatocytes, Myrcludex B-modified pegylated 
liposomes should be developed and tested in vitro as well as in vivo. Liposomes should be modified 
with different variations of Myrcludex B (e.g., truncated peptide sequences and various fatty acid 
modifications), to test their effect on liposome formulation, physico-chemical liposome 
characteristics, and targeting ability. Specificity of cellular binding, uptake mechanism and its 
efficiency as well as intracellular transport should be investigated in several human cell lines in vitro. 
In vivo experiments will be necessary to analyze the biodistribution of the nanoparticulate drug 
delivery system on an organ as well as cellular level and to verify hepatocyte specificity. 208 In vivo 
imaging in mice will be performed in collaboration with the Radiopharmaceutical Chemistry Division 
at the University of Heidelberg (Group of Prof. Dr. W. Mier) using established protocols. 209,210 
 
With this approach, it will be possible to develop a novel and ASGPR-alternative 
nanoparticle-based drug delivery platform to deliver small molecules or nucleic acids efficiently and 
with high specificity to hepatocytes. 
 
II. Plasmid DNA-based Gene Delivery  
There is an increasing interest in non-viral gene delivery systems. Future projects should 
focus on the development of a novel nanoparticle platform to deliver nucleic acids efficiently and 
with low cytotoxicity to hepatocytes. An ideal nucleic acid delivery system for biomedical 
applications should fulfill following criteria: small size (<120 nm), neutral or slightly negative zeta 
potential, high nucleic acid encapsulation, efficient cellular uptake and endosomal release, 
biocompatibility, and easy manufacturing process. 102 Most approaches described in literature for 
cellular delivery of nucleic acids suffer from major drawbacks.  
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First, the synthesis route of many polymers used for the design of nanomaterials is complex 
and offers limited control over polymerization.184 Second, commonly used nanoparticle preparation 
techniques such as the film-rehydration method are time-consuming, not amendable to scale up, and 
characterized by poor encapsulation efficiency. 211 So far, these systems are not being used in clinical 
applications, largely because of their complex design leading to technical challenges with respect to 
GMP manufacturing and product registration. Finally, many developed gene delivery systems have a 
positive charge (i.e., needed for the pDNA complexation). 212 This leads to unspecific cellular uptake 
and rapid sequestration in the lung after i.v. injection. 120 Thus, systemic administration in vivo is not 
possible. One solution to this problem are pH responsive delivery systems. 213 Ionizable groups offer 
the possibility to formulate nanoparticles at low pH thus enhancing intravesicular pDNA 
complexation. At physiological pH in circulation the nanoparticle surface has a neutral charge thus 
offering optimal physico-chemical properties for a systemic administration (Figure 8). 
 
1. Novel Nanomaterials: Ionizable Amino-lipids 
Among the various nanomaterials, liposomal formulations can be considered to be safe, 
biocompatible and non-immunogenic. Therefore, these delivery systems are a promising alternative 
to viral vectors for gene therapy. In general, neutral and pegylated phospholipids in combination 
with cholesterol are used for the formation of liposomes. Such sterically stabilized liposomes were 
shown previously to be ideal candidates to implement targeted drug delivery strategies. 103 However, 
for efficient loading of expression plasmids, cationic helper lipids are needed.  
Therefore, a novel ionizable amino-lipid library should be synthetized to facilitate pDNA 
encapsulation within liposomal carriers as well as to enhance endosomal escape, intracellular release 
and transgene expression. The ionizable lipids are supposed to have a high buffering capacity in the 
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pH range between 5.0 and 6.0 and therefore induce rupture of endosomal membranes via “proton 
sponge” mechanism enabling endosomal escape. Screening of the lipid library will help to identify 
lead structures, which can be further optimized by chemical methods. This part of the project will be 
carried out in cooperation with the Division of Chemical Lipidology at the University of Fribourg 
(Group of Prof. Dr. Andreas Zumbühl).  
 
In order to establish a versatile platform technology, efficient technologies are needed to 
prepare liposomal carriers and to load them with pDNA. Microfluidics is a recent technology, 
which facilitates this process (Figure 10). It allows the rapid and highly controlled mixing of the 
nanomaterial (i.e., amino-lipids or phospholipids) with nucleic acids (i.e., plasmid DNA). 214–216 Batch 
sizes range from a few hundred microliters to production scale volumes. This technology is thus 
amendable to industrial scale production under GMP conditions. 
 
 
Figure 10: Schematic illustration of microfluidics approach. Nucleic acid loaded nanoparticles are 
prepared using microfluidics. The microfluidics device has two inlet channels converging to a single 
staggered herringbone micromixer. The lipid mix (ethanol) and pDNA (formulation buffer) solution are 
injected simultaneously. In the micromixer the components are mixed and pDNA loaded nanoparticles 
are formed. This process is controllable and highly reproducible. Figures are adapted from Rungta et 
al. and Stroock et al. 199,214 
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Finally, the developed nanoparticles should be tested in vitro for their cytocompatibility and 
transfection efficiency. Several assays should be used to uncover potential safety issues including 
general cytotoxicity, reactive oxidative species (ROS) and superoxide production, apoptosis, or 
hemolysis. To investigate mechanisms of intracellular pDNA release from the endosomal 
compartment and its nuclear translocation, labeled nanocarriers should be used. To explore the 
transfection efficiency of amino-lipid containing formulations in vitro, expression of reporter genes 
such as green fluorescent protein (GFP) or of the very sensitive marker luciferase can be studied.  
 
The design of next-generation nanoparticles and the mechanistic insights from such an 
research project will not only be instrumental to optimize gene targeting strategies but will also 
contribute to ongoing efforts in this field of research to better control expression of transfected 
genes on a cellular level. 
 
III. Combination of Targeting and Gene Delivery Approach 
For the implementation of gene therapy approaches, targeted nucleic acid loaded 
nanoparticles are needed. These delivery systems should fulfill following criteria: efficient nucleic acid 
loading, stealth properties, small size, specific target-binding and uptake, endosomal escape, 
intracellular pDNA release (Figure 11). In addition, these systems should be safe and non-
immunogenic.  
To develop such a targeted gene delivery approach, the above mentioned targeting strategy 
(Section I) should be combined with novel gene delivery nanomaterials (Section II). This offers the 
possibility to enhance cellular uptake and promote intracellular release. 
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Figure 11: Hepatocyte-specific gene delivery. Ligand-modified DNA lipid nanoparticles circulate in the 
blood stream. (1) After passage of the hepatic sinusoids, the nanoparticles specifically bind to 
hepatocyte membrane receptors. This interaction triggers internalization. (2) The pH in endosomes 
decreases due to proton pumps. (3) Acidification of endosome results in protonation of ionizable lipids 
which finally causes endosomal escape of plasmid DNA via proton sponge effect. (4) Via the nuclear 
pore the nucleic acid enters the nucleus. The delivered gene gets transcribed and finally leads to the 
translation of an exogenous protein. 
 
1. Targeted Gene Delivery 
In the last phase of the project, the potential of the novel targeted gene delivery system will 
be confirmed in vitro and possible future clinical applications will be explored in vivo. The targeted 
gene delivery system will be optimized with respect to physico-chemical features for an in vivo 
application (e.g., stability, increased circulation half-life, or biocompatibility). Optimal lipid 
compositions will be identified based on expression levels of the transfected protein of interest.  
Thus, it is the aim of these experiments to obtain a gene delivery system, which is optimized 
both with respect to cell-specific targeting as well as cellular uptake, intracellular release and 
subsequent gene expression of the delivered pDNA. 
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IV. Future Clinical Applications 
In conclusion, this research project aims to close the gap of efficient therapeutics with the 
development of an innovative and functional platform technology for the expression of therapeutic 
genes specifically in hepatocytes. A highly selective targeting ligand will be combined with optimized 
nanomaterials for gene delivery. With this novel therapeutic strategy, we have the possibility to 
address unmet medical needs. The proposed technology can potentially be used for several clinical 
applications.  
First, the delivery of larger nucleic acids could open the door to promising gene editing 
approaches such as the CRISPR/Cas9 or zinc-finger technology for in vivo applications. 217 Second, 
the expression of oncotoxic proteins is a promising approach to treat hepatocellular carcinoma 
more efficiently 218. The treatment options for advanced stages of HCC are limited and the use of 
small molecule therapeutics is often limited due to the development of resistance. Gene therapy 
would offer new possibilities to overcome these limitations. An interesting strategy is the expression 
of oncotoxic proteins inside tumor cells. For instance, the parvovirus-H1 derived non-structural 
protein (NS1) induces tumor-selective apoptosis. 219 Several endogenous proteins are redirected by 
NS1 resulting in ROS production, DNA damage, actin skeleton rearrangement, cathepsin B release, 
or caspase activation and finally tumor cell death. 220 Due to its various induced toxicity pathways, the 
development of resistance to NS1 is not possible. Thus, cancer cells produce their own suicide 
protein. Finally, patients with orphan monogenetic liver disorders (i.e., rare diseases) would highly 
benefit from novel therapeutic options, which replace the mutated enzyme by delivery of their 
encoding DNA sequences 61,221. For instance, an UGT1A1 gene-replacement therapy for patients 
with hereditary Crigler-Najjar syndrome would offer an interesting treatment strategy, which 
outperforms all existing therapeutic options.  
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ABBREVIATIONS 
ADC Antibody Drug Conjugate MPS Mononuclear Phagocyte System 
ApoE/B Apolipoprotein E/B NAGS N-acetyl glutamate synthetase 
ARG Arginase NDDS Nanoparticulate drug delivery system
ASGPR Asialoglycoprotein receptor  NS1 Non-structural protein 
ASL Argininosuccinate lyase NTCP Sodium-Taurocholate Cotransporting 
Polypeptide 
ASS Argininosuccinate synthetase OTC Ornithine transcarbamylase 
BCLC Barcelona Clinic Liver Cancer  PBS Phosphate Buffered Saline 
CAR Coxsackie-adenovirus receptor  PCSK9 Proprotein Convertase Subtilisin/Kexin 
type 9 
Cas9 CRISPR-associated PDGF Platelet-Derived Growth Factor 
CPS Carbamoylphosphate synthetase pDNA plasmid DNA
CRD Carbohydrate Recognition Domain PEG Polyethylene glycol 
CRISPR Clustered Regularly Interspaced Short 
Palindromic Repeats 
PMOXA Poly(2-methyloxazoline) 
DNA Deoxyribonucleic acid RES Reticuloendothelial system 
DSPC 1,2-Distearoyl-sn-glycero-3-
phosphocholine 
RFA Radiofrequency Ablation  
DSPE 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine  
RNA Ribonucleic acid  
FAH Fumarylacetoacetate hydrolase RNAi RNA interference 
FAP Familial Amyloid Polyneuropathy ROS Reactive Oxidative Species  
G6PD Glucose-6-phosphate dehydrogenase SAXS Small-Angle X-ray Scattering 
Gal Galactose SC Stellate Cells 
GalNAc N-acetylgalactosamine  scFv Single-chain (variable fragment) 
antibody 
GFP Green Fluorescent Protein SEC Sinusoidal Endothelial Cells  
GMP Good Manufacturing Practice siRNA small interfering RNA 
GSD Glycogen Storage Diseases TACE Transarterial chemoembolization 
HBV Hepatitis B Virus TEM Transmission Electron Microscopy
HC Hepatocytes TFR Transferrin receptor  
HCC Hepatocellular carcinoma  TGF Transforming Growth Factor  
HCV Hepatitis C Virus TIMP Tissue inhibitors of matrix 
metalloproteinases 
KC Kupffer Cells  TTR Transthyretin
LDLR Low-Density Lipoprotein Receptor UGT1A1 UDP-glucuronosyltransferase 1A1 
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